Literature DB >> 26732082

Response of symptomatic brain metastases from HER-2 overexpressing breast cancer with T-DM1.

C L Gorter de Vries1, S C Linn2, D Brandsma3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26732082     DOI： 10.1007/s11060-015-2045-1

Source DB:  PubMed          Journal:  J Neurooncol        ISSN： 0167-594X            Impact factor:   4.130


× No keyword cloud information.
  6 in total

1.  Clinical outcome of patients with brain metastases from HER2-positive breast cancer treated with lapatinib and capecitabine.

Authors:  G Metro; J Foglietta; M Russillo; L Stocchi; A Vidiri; D Giannarelli; L Crinò; P Papaldo; M Mottolese; F Cognetti; A Fabi; S Gori
Journal:  Ann Oncol       Date:  2010-08-19       Impact factor: 32.976

2.  Breast cancer brain metastases responding to primary systemic therapy with T-DM1.

Authors:  Rupert Bartsch; Anna S Berghoff; Matthias Preusser
Journal:  J Neurooncol       Date:  2013-09-25       Impact factor: 4.130

3.  Activity of T-DM1 in HER-2 positive central nervous system breast cancer metastases.

Authors:  Sofia Torres; Pejman Maralani; Sunil Verma
Journal:  BMJ Case Rep       Date:  2014-08-14

4.  Trastuzumab emtansine for HER2-positive advanced breast cancer.

Authors:  Sunil Verma; David Miles; Luca Gianni; Ian E Krop; Manfred Welslau; José Baselga; Mark Pegram; Do-Youn Oh; Véronique Diéras; Ellie Guardino; Liang Fang; Michael W Lu; Steven Olsen; Kim Blackwell
Journal:  N Engl J Med       Date:  2012-10-01       Impact factor: 91.245

Review 5.  The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine.

Authors:  Jeffrey S Ross; Elzbieta A Slodkowska; W Fraser Symmans; Lajos Pusztai; Peter M Ravdin; Gabriel N Hortobagyi
Journal:  Oncologist       Date:  2009-04-03

6.  Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial.

Authors:  G Gebhart; L E Lamberts; Z Wimana; C Garcia; P Emonts; L Ameye; S Stroobants; M Huizing; P Aftimos; J Tol; W J G Oyen; D J Vugts; O S Hoekstra; C P Schröder; C W Menke-van der Houven van Oordt; T Guiot; A H Brouwers; A Awada; E G E de Vries; P Flamen
Journal:  Ann Oncol       Date:  2015-11-23       Impact factor: 32.976
  6 in total
  3 in total

1.  Diagnosis and treatment of brain metastases from solid tumors: guidelines from the European Association of Neuro-Oncology (EANO).

Authors:  Riccardo Soffietti; Ufuk Abacioglu; Brigitta Baumert; Stephanie E Combs; Sara Kinhult; Johan M Kros; Christine Marosi; Philippe Metellus; Alexander Radbruch; Salvador S Villa Freixa; Michael Brada; Carmine M Carapella; Matthias Preusser; Emilie Le Rhun; Roberta Rudà; Joerg C Tonn; Damien C Weber; Michael Weller
Journal:  Neuro Oncol       Date:  2017-02-01       Impact factor: 12.300

Review 2.  Mechanisms and Therapy for Cancer Metastasis to the Brain.

Authors:  Federica Franchino; Roberta Rudà; Riccardo Soffietti
Journal:  Front Oncol       Date:  2018-05-24       Impact factor: 6.244

3.  Efficacy of T-DM1 for leptomeningeal and brain metastases in a HER2 positive metastatic breast cancer patient: new directions for systemic therapy - a case report and literature review.

Authors:  Giuseppina Rosaria Rita Ricciardi; Alessandro Russo; Tindara Franchina; Silvia Schifano; Giampiero Mastroeni; Anna Santacaterina; Vincenzo Adamo
Journal:  BMC Cancer       Date:  2018-01-25       Impact factor: 4.430
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.